Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Patients' Lives

There’s a simple purpose that sits at the heart of our business: to transform the lives of patients with specialist conditions.

Watch the video

2013 Annual Report

We are focused on growing Shire by developing and marketing innovative specialty medicines that address significant unmet patient needs.

View our Annual Report

Download our Annual Report 2013 (PDF)

Shire launches new Clinical Trials website serves as the source for Shire-sponsored clinical trials, as well as a resource for education and awareness about clinical research. It also provides increased transparency into Shire’s data sharing practices.


Full Year 2013

Flemming Ornskov, MD, Chief Executive Officer and Graham Hetherington, Chief Financial Officer present Shire's Full Year results for 2013.

View the Press Release


Replay the Webcast 


Download the Shire IR App


Download the Presentation



Shire completes acquisition of

Shire’s acquisition of ViroPharma - a high growth, rare disease biopharmaceutical company – is an excellent strategic fit that will significantly enhance our rare disease portfolio.

View the Press Release

Shire's Stance 

Shire opposes the misuse, abuse, and diversion of prescription ADHD medicines.

Read more here


Share price

17 Apr 2014
At least 15 minutes delayed

Our products

Shire has a wide range of products on the market and will ensure that it can make more products available in the future.


Our responsibility

What Responsibility Means

What Responsibility means to Shire. Read more here.

Our stance on ADHD

Shire Opposes Misuse, Abuse and
Diversion of Prescription ADHD
Medicines. Read more here.

Shire collaborates with Sedex

Read about our efforts in qualifying our suppliers to ensure they are doing business in a manner that reflects our own values.